drugset
Drugs / CBT-1
last change Sep 2020 re-read 2 minutes ago

CBT-1

Small molecule

Developed for
breast disorder · cervix disorder · lung disorder · ovarian disorder · sarcoma · non-small cell lung carcinoma
Investigated by
CBA Research · National Cancer Institute (NCI)

Trials 2 · a red edge is where a trial was stopped

today NCT03002805 · Ph 1 NCT00972205 · not/applicable
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03002805 Mar 2018 → Sep 2020 sarcoma CBA Research Unknown No outcome recorded
Phase not applicable1 trial
— NCT00972205 Dec 2007 → Jun 2009 breast disorder, cervix disorder, lung disorder, ovarian disorder National Cancer Institute (NCI) Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00437749 Comparator Aug 2001 → Jul 2010 non-small cell lung carcinoma CBA Research Terminated No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as CBT-1 “CBT-1® is an orally administered bisbenzylisoquinoline Pgp inhibitor being evaluated clinically.” PMID 22416063 ↗ Mar 2012
3

NCT00972205 ↗

NCT03002805 ↗

NCT00437749 ↗
Action Inhibit “CBT-1 is a natural product currently in clinical trials as an inhibitor” NCT00437749 ↗
Modality Small molecule “CBT-1® is an orally administered bisbenzylisoquinoline Pgp inhibitor being evaluated clinically.” PMID 22416063 ↗ Mar 2012
Route Oral “CBT-1 500 mg/m\^2 oral dose daily for 7 days in divided doses 3 times a day.” NCT00972205 ↗